This company has shut down. Aerami Therapeutics is no longer operating — its last tracked round was a Series B in 2022.
Explore the Startup GraveyardAerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases.
Aerami Therapeutics has raised $5.4M in total funding. The most recent round was Series B. The last funding was announced in September 2022.
Aerami Therapeutics's investors include SternAegis, Molex Ventures, John Patton.
Aerami Therapeutics is headquartered in Durham, United States.
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases.
Aerami Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aerami Therapeutics — Funding & Investors." VCBacked, September 20, 2022, https://www.vcbacked.co/company/aerami-therapeutics. Accessed November 15, 2026.
VCBacked. (2022). Aerami Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/aerami-therapeutics
{{cite web |title=Aerami Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aerami-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Aerami Therapeutics? Request a listing update